Click on image to view larger version.

Figure 1 Schematic representation of study design and numbers of patients. At screening, patients were required to: 1) have a high-density lipoprotein cholesterol (HDL-C) level <44 mg/dl for men and <54 mg/dl for women, and 2) be on statin therapy or have a low-density lipoprotein cholesterol (LDL-C) level >130 mg/dl. A total of 69 patients were already receiving statin therapy at screening. Sample size was calculated based on earlier torcetrapib studies, with 25 patients per group yielding 80% power to detect a 25% treatment difference in HDL-C, assuming a common standard deviation of 30.5% and 2-sided t test with 5% type I error. LOCF = last observation carried forward (i.e., patients with baseline plus 1 post-baseline HDL-C measurement); R = randomization.